Sachin D. Patel has acquired 5,23,560 equity shares of Gujarat Themis Biosyn Limited from Pharmaceutical Business Group India Limited in an inter-se transfer within the promoter group. The transaction, completed on July 30, 2026, was executed at a price of ₹382 per share. This acquisition increases Patel’s stake in the company from 2.29% to 2.77% of the total diluted share capital, while the seller’s holding decreases from 47.02% to 46.54%. The move reflects internal restructuring among key stakeholders without altering the overall promoter group control.

The disclosure was submitted to the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 4, 2026, under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. A prior intimation regarding this inter-se transfer was filed with the exchanges on July 14, 2026, complying with the requirement under Regulation 10(5) to disclose such transactions four working days prior to execution. The exemption from making an open offer was claimed under Regulation 10(1)(a)(ii), which applies to transfers between persons named as promoters in the shareholding pattern.

Transaction Details

Shareholding Structure

The table below outlines the change in shareholding for both the acquirer and the transferor following the transaction:

| Entity | Pre-Transaction Shares | Pre-Transaction % | Post-Transaction Shares | Post-Transaction % | |---:|:---| | Sachin D. Patel | 24,97,200 | 2.29% | 30,20,760 | 2.77% | | Pharmaceutical Business Group India Limited | 5,12,40,000 | 47.02% | 5,07,16,440 | 46.54% |

What the Numbers Show

The transaction represents a consolidation of holdings within the promoter circle rather than an entry by new external capital. With the transferor, Pharmaceutical Business Group India Limited, retaining a substantial 46.54% stake, the overall promoter group influence remains stable. The specific price of ₹382 per share serves as a reference point for recent valuation benchmarks within the promoter group, though it does not reflect open market trading dynamics. Such inter-se transfers are common for estate planning or internal realignment of equity among founding families and associated entities.

Gujarat Themis Biosyn will host a conference call on August 10, 2026, to discuss its financial performance for the first quarter of fiscal year 2027 (1QFY27). The virtual meeting is scheduled for 14:30 IST and aims to provide stakeholders with insights into the company's recent operational and financial results.

Earnings Call Details

The conference call follows the board meeting held on August 7, which was convened to review the Q1 results. This investor interaction serves as a platform for management to address queries from analysts and institutional investors regarding the quarter's performance. The event is organized in compliance with Regulation 30 and Regulation 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Management Participation

Senior leadership from Gujarat Themis Biosyn will participate in the discussion to provide clarity on strategic initiatives and financial outcomes. The key representatives attending the call include:

• Dr. Sachin Patel, Managing Director
• Mr. Rajneesh Anand, Non-executive Director
• Mr. Krupesh Patel, Chief Financial Officer

The conference call is being facilitated by 360 ONE CM Research, which will manage the logistics and participant registration. Investors can access the meeting via a dedicated virtual link or through dial-in numbers provided for domestic and international participants.

Access Information

Participants are required to register using the Diamond Pass link provided by the research agency. For those preferring audio access, universal dial-in numbers are available for India, while toll-free options are listed for various international markets including the USA, UK, Australia, and others. The company has ensured broad accessibility to facilitate engagement with its global investor base.